Molgramostim Completed Phase 3 Trials for Metastatic Renal Cell Carcinoma ( mRCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01265901IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma